This meta-analysis was performed to evaluate the efficacy and safety of addition of tiotropium to standard treatment regimens for inadequately controlled asthma.
95% CI 0.04 to 0.13 L, P<.001 respectively), FVCAUC 0-3h (WMD 0.11 L, 95% CI 0.06 to 0.15 L, P<.001). The mean change in ACQ-7 (WMD -0.12, 95% CI -0.21 to -0.03, P=.01) was markedly lower in tiotropium group, but not clinically significant.
There were no significant differences in AQLQ score (WMD 0.09, 95% CI -0.01 to 0.20, P=.09), night awakenings (WMD 0.00, 95% CI -0.05 to 0.05, P=.99) or rescue medication use (WMD -0.18, 95% CI -0.36 to 0.00, P=.06). No significant increase was noticed in adverse events in tiotropium group (OR 0.80, 95% CI 0.62 to 1.03, p=.08).
Conclusion
Addition of tiotropium to standard treatment regimens has significantly improved lung function without increasing adverse events in patients with inadequately controlled asthma. Long-term trials are required to assess the effects of addition of tiotropium on asthma exacerbations and mortality.
INTRODUCTION
Asthma is a chronic respiratory disease characterized by reversible airway obstruction that is secondary to airway inflammation and excessive smooth muscle contraction [1] . A great proportion of patients with asthma are suffering recurring symptoms and exacerbations, even after administration of high doses of inhaled corticosteroids (ICSs) combined with a long-acting β2 agonists(LABAs). The Global Initiative for Asthma (GINA) guidelines recommend addition of another medication to achieve optimal asthma control, such as anti-leukotrienes, theophyllines, anti-IgE, and immunosuppressants (e.g., systemic corticosteroids or cyclosporine) [2] . Nevertheless, many patients do not achieve symptom control with current options.
Furthermore, there are also concerns about the safety of regular use of high-dose LABAs and ICSs in patients with asthma. Adding a second bronchodilator with a different mechanism of action into the treatment of inadequately controlled asthma might be a new available way to address the problem.
Parasympathetic nervous system is an important neural pathway controlling airway smooth muscle by muscarinic receptors. Stimulation of the parasympathetic nerve can result in broncho-constriction, bronchial vasodilatation and mucus secretion.
Moreover, recent investigations revealed that non-neuronal cholinergic system was widely expressed in epithelial cells, eosinophils, submucosal glands, smooth muscle cells, and a variety of immune cells including lymphocytes, macrophages, and mast cells in the airway, suggesting that non-neuronal cholinergic signals played an important role in the pathophysiology of asthma [3] . Therefore, it seems favorable to add an anti-cholinergic agent to block cholinergic signals in the treatment of asthma.
Previous studies found no long-term benefits of short-acting anti-cholinergic agents in patient with persistent asthma [4, 5] . Tiotropium bromide is an anti-cholinergic agent with long-lasting action which is characterized by a slow dissociation from acetylcholine M1 and M3 receptors [6, 7] . Current COPD treatment guidelines recommend tiotropium as the first-choice long-acting bronchodilator for maintenance therapy in moderate or severe COPD because of its effectiveness, safety, and convenient once-daily dosing [8] . However, little has been known about its efficacy in asthma. In animal models of allergic asthma, it was shown that tiotropium inhibited airway inflammation and reduced airway remodeling [9, 10] . Recently, beneficial effects of tiotropium maintenance dosing in patients with asthma have been reported in clinical study. Peters et al. demonstrated that addition of tiotropium improved symptoms and lung function in patients with mild-to-moderate asthma which had been poorly controlled with only low-dose ICS, and its effects were found to be non-inferior to those of salmeterol [11] .In addition, Bateman et al. reported that tiotropium was not inferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma [12] and that addition of tiotropium to high-dose ICS plus LABA improved lung function in patients with poorly controlled severe asthma [16] .
The aim of the present meta-analysis was to evaluate the efficacy and safety of tiotropium versus placebo in asthmatic patients whose symptoms were inadequately controlled with standard treatment regimens (i.e., ICS with or without LABAs).
METHODS

Data Sources
We searched Pubmed, EMBASE, Medline and CENTRAL databases and Clinicaltrials.gov for trials published from January 1980 to December 2012 using the following search terms: "(tiotropium OR 'Ba 679 BR' OR Spiriva) AND asthma" , and supplemented by hand searching of leading respiratory journals and conference abstracts. All publications and abstracts in English language were considered.
Moreover, a further search in April 2013 did not identify additional trials that fulfilled our search criteria.
Study selection
The inclusion criteria of trials were as follows: a) double-blinding randomized controlled trials (RCT) on tiotropium compared with placebo; b) duration of at least 4 weeks; c) more than 12 years of age; d) patients with symptomatic asthma even after treatment with ICS or ICS plus LABAs; e) a history of asthma without other lung diseases, and f) the modified Jadad score of 4 points or above.
Quality assessment
The methodological quality of each study was assessed by the Modified Jadad Scale (7 points) [13] , which scores trials according to randomization, concealment of allocation, double blinding, withdrawals and dropouts. Studies with a score of 4 points or above were included.
Data extraction
Data extraction was based on reported statistics (means, SD and SE) for the intention to treat population. Two reviewers (TIAN Jing-wei and CHEN Jing-wu) independently extracted data from the selected studies. If disagreement arose, all the authors conferred till a consensus was arrived at. Authors of a publication were contacted if only its abstract was available or data were missing. Primary outcomes were changes from baseline in morning and evening peak expiratory flow (PEF).
Secondary outcomes included changes from baseline in peak and trough forced receiving tiotropium and those receiving placebo were pooled using a fixed effects model when there was no evidence of significant heterogeneity in the analysis; if significant heterogeneity was found, a random-effects model was used [14] . Publication bias was examined using funnel plots [15] .
RESULTS
Search results
The progress of searching and selecting trials is presented in Figure 1 . Of the 42
English articles were screened, we excluded 37 that were either not relevant or incomplete in data. To reduce heterogeneity across different trials, we only selected those comparing tiotropium (5 microgram qd, with Respimat® inhaler ) with placebo at both baseline and end of treatment period. Five articles involving 1648 participants, including six RCTs-three parallel RCTs and three crossover RCTs that met our inclusion criteria were selected for the present meta-analysis. Characteristics of the trials we included were shown in Table 1 and Table 2 . All data adopted in the present study had been published openly at either the website Clinicaltrial.gov or journals.
Primary outcome
Change in morning and evening PEF . (Fig. 3) .
Change in FVC
Five included trials reported FVC. Although no obvious improvements in peak FVC, trough FVC and FVCAUC 0-3h were observed in one study, the cumulative analysis showed a statistically significant improvement respectively in peak FVC P<.001)in tiotropium group. (Fig. 4) .
Asthma control
Of the trials included, three reported score of ACQ-7 (Asthma Control Questionnaire). ACQ is a questionnaire consisting of a seven point scale ranging from 0(no impairment) to 6(maximum impairment), with a minimal clinically important difference of 0.5 units. The score was statistically lower with tiotropium than with placebo (WMD -0.12; 95% CI -0.21 to -0.03; p=.01).However, the improvement in ACQ-7 did not achieve the minimum clinical important difference of 0.5 units in asthma.
Night awakenings
Three trials showed data of mean number of night awakenings during the last week of treatment. The cumulative analysis showed no statistical differences between patients receiving tiotropium and placebo (WMD 0.00; 95% CI -0.05 to 0.05; I 2 =0%; P=.99). (Fig. 5) .
Rescue medication use
Mean number of puffs of rescue medication during the whole day in the last week of treatment was reported in five trials. Although the pooled analysis showed a dropping trend in patients receiving tiotropium compared with those receiving placebo (WMD -0.18; 95% CI -0.36 to 0.00; I 2 =0%; P=.06), the difference was not statistically significant. (Fig. 6 ).
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Quality of Life
Three trials reported AQLQ (Asthma Quality of Life Questionnaire). Although the cumulative analysis showed a little decrease in patients receiving tiotropium compared with those receiving placebo (WMD 0.09; 95% CI -0.01 to 0.20; I 2 =0%;
P=.09), no significant difference between the two groups was observed.
Adverse events
Incidence of adverse events was evaluated in 6 studies. The overall cumulative incidence of adverse events was 44.0% in tiotropium group and 47.4% in placebo group. All the adverse events reported in at least two trials were shown in Table 3 .
The overall analysis showed no statistically significant increase in total adverse events in tiotropium group (OR 0.80; 95% CI 0.62 to 1.03; p=0.08). Among adverse events, asthma exacerbation (OR 0.69; 95% CI 0.54 to 0.89; p=0.004）and peak expiratory flow rate decline decreased (OR0.70; 95% CI 0.52 to 0.96; p=0.02) markedly in tiotropium group. There was no statistical significant difference in serious adverse events between the two groups (OR 1.15; 95% CI 0.74 to 1.79; p=0.54) (Fig. 7) .
DISCUSSION
Asthma is a commom airway obstructive diseases and bronchodilators are very important to the management of symptoms of asthma [21] . The added benefits of combining two long-acting bronchodilators with different modes of action have been observed in patients with COPD [22] . Titropium will be approved by FDA in next months for asthma. However, guidelines do not specifically recommend addition of an RESPIRATORY CARE Paper in Press. Published on October 29, 2013 as DOI: 10.4187/respcare.02703
inhaled long-acting anticholinergic drug to current treatment of asthma [23] . This meta-analysis incorporates 6 RCT and includes data from 1648 patients with inadequately controlled asthma. To our knowledge, to date this is the first meta-analysis of the efficacy and safety of tiotropium versus placebo regarding , it should be noted that the increases were in patients who were receiving ICSs or ICSs plus LABAs. There were no significant differences between tiotropium and placebo groups in AQLQ, night awakenings or rescue medication use. Although a statistically significant difference was reported for ACQ-7, it was not clinically showed no significant differences between tiotropium and placebo groups in AQLQ.
The AQLQ was developed to measure patients' functional experiences over a 2-week period, and it asks patients to recall their experiences during the previous days.
Therefore, it is not suitable for capturing the rapidly changing experiences that occur during an acute asthma exacerbation [30] . Furthermore, although the difference was not statistically significant, it was noticeable that there were trends towards the improvement of AQLQ (P=.09) and a reduction in the number of rescue medication use(P=.06) among patients treated with tiotropium. It indicated that the increase in
sample size might get a positive result.
It was so surprising for us to find in this meta-analysis a decreasing trend, but statistically insignificant, in total adverse events among patients treated with tiotropium. Among total adverse events, asthma exacerbation and peak expiratory flow rate decline decreased obviously in tiotropium group, which might account for the decreasing trend in total adverse events among patients treated with tiotropium. In addition, no significant increase in serious adverse events was observed. Dry mouth, urinary retention and cardiovascular events are most concerning adverse event of anticholinergic agents. This analysis showed that these adverse events were reported in a very small part of the included patients, which were of mild to moderate severity according to the statements in the relevant articles. It should be noticed that the low incidence of cardiovascular events might have resulted from the exclusion of patients with serious cardiovascular diseases in the trials included for this meta-analysis.
Excess cardiovascular events might have been anticipated in such patients.
We are very interested in the studies on tiotropium that used the DPI in asthma, because Handihaler is the only device available for tiotropium in China now. We found 6 RCTs on tiotropium that used the DPI in asthma population. Of the 6 RCTs, one evaluated the addition of tiotropium to an inhaled glucocorticoid, as compared with a doubling of the inhaled glucocorticoid or the addition of salmeterol [11] . The results showed that tiotropium improved symptoms and lung function in patients with inadequately controlled asthma when added to an inhaled glucocorticoid. Its effects appeared to be equivalent to those with the addition of salmeterol. To reduce RESPIRATORY CARE Paper in Press. Published on October 29, 2013 as DOI: 10.4187/respcare.02703
heterogeneity of different trials, we only selected the data comparing tiotropium with placebo. Another RCT was designed to determine the spirometric effects of tiotropium in COPD patients with concomitant asthma [24] . The results showed that the patients with COPD and concomitant asthma achieved spirometric improvements with tiotropium along with symptomatic benefits as seen by reduced need for rescue medication. To reduce heterogeneity of different trials, we also only selected data of asthma patients without other lung diseases. A RCT by Fardon T compared tiotropium with placebo, but the data it provided were not suitable for our meta-analysis [25] .
Three RCTs investigated the protection of tiotropium with DPI device versus placebo or other anticholinergic drugs against methacholine-induced bronchoconstriction in asthma [26, 27, 28] , but they were not relevant to this meta-analysis. Hence, we excluded the 6 RCTs on tiotropium that used DPI before ultimate analysis.
The main strength of our study was inclusion of a large pool of patients with inadequately controlled asthma, allowing us to perform robust analysis of clinically relevant outcomes following addition of tiotropium versus placebo to standard treatment strategy. The trials included in this analysis were of good quality and used almost identical designs with regard to inclusion and exclusion criteria. And the clinical characteristics of study populations were quite homogeneous. However, the results should be interpreted with caution because they might have been influenced by other factors. Firstly, there were differences in trial duration. The duration of treatment in the most trials here was too short to allow adequate evaluation of long-term efficacy and safety of tiotropium. Although a meta-analysis showed a 46%
relative risk increase in death in COPD trials that used 5ug tiotropium Respimat® inhaler [29] , it has not been elucidated whether the increase in death in asthma was brought about by the use of Respimat® inhaler. Further long-term studies are anticipated to answer this question. Secondly, the patients with inadequately controlled asthma included in this meta-analysis were over 12 years old, free from other pulmonary diseases and in non-smoking status. Therefore, it is inappropriate to generalize the results of this meta-analysis to all asthma patients. Thirdly, the trials included had different criteria for use of co-medications. In current trials, tiotropium is an additional medicine to standard treatment regimens rather than a first-choice medicine.
Clinical homogeneity of the trials resulted in statistical homogeneity for all outcome measures across the trials. Selection bias was avoided using a systematic search strategy, and we specified the inclusion and exclusion criteria. Furthermore, two reviewers independently evaluated the selected studies and a third reviewer was consulted to reach consensus if necessary. Double-counting of patients from overlapping publications was avoided. Funnel plots for the primary endpoint showed no clear evidence of publication bias. Selective reporting of secondary end points and non-intention to treat reports in published manuscripts may bias results. We minimized this bias by obtaining supplemental data for included studies.
CONCLUSIONS
This meta-analysis indicates that addition of tiotropium to the treatment of Table 3 Adverse events with tiotropium compared with placebo.
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Figure 1
Flow chart showing strategy for identification of relevant studies. NA, not available; RCT, randomized controlled trials.
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